Are CXCR4 Antagonists Making a Comeback in Cancer Chemotherapy? Reporter: Stephen J. Williams, Ph.D. Biospace News reported that Massachusetts based X4 Pharmaceuticals is using $34B to launch two clinical trials on its CXCR4 inhibitor X4P-001 in refractory clear cell renal cell carcinoma and refractory epithelial ovarian cancer. The full report is below: X4 Pharma Uses […]![]()
